Oncolytics Biotech (NASDAQ:ONCY) reported published preclinical findings showing that pelareorep increased markers associated with immune activation in hepatocellular carcinoma (HCC), the most common form of liver cancer.
Cosmos Health (NASDAQ:COSM) reported record second-quarter 2026 revenue exceeding $15 million at its CosmoFarm pharmacy distribution subsidiary.
Carnival Corporation (NYSE:CCL) reported third-quarter 2026 financial results, with record revenue and stronger operating expectations for the full year.
Propanc Biopharma (NASDAQ:PPCB) reported fiscal 2026 financial results and provided an update on development plans for PRP, its investigational cancer therapy candidate.
Lite Strategy (NASDAQ:LITS) reported fiscal 2026 results for the year ended June 30, marking its first fiscal year operating under a Litecoin treasury strategy.
1-800-FLOWERS.COM (NASDAQ:FLWS) announced a definitive agreement to sell PersonalizationMall.com and Things Remembered to PlanetArt, LLC for approximately $45 million in cash.
Iovance Biotherapeutics (NASDAQ:IOVA) raised its full-year 2026 revenue guidance following stronger-than-expected demand for its commercial products, Amtagvi and Proleukin.
Nurix Therapeutics (NASDAQ:NRIX) announced that it achieved a $7 million research milestone under its collaboration with Pfizer (NYSE:PFE) to develop degrader antibody conjugates.
BeyondSpring (NASDAQ:BYSI) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Plinabulin in combination with docetaxel for previously treated advanced non-squamous lung cancer.
BIO-key (NASDAQ:BKYI) announced a partnership with Al Majlis Group to introduce its identity security platform to organizations in the United Arab Emirates and Saudi Arabia.
GARANTA JÁ SEU GRAFA EDGE
Vamos ativar um teste de 30 dias do Edge como presente de boas-vindas
